Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus HERPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus HERPLEX.
DENDRID vs HERPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
Inhibits viral DNA polymerase after phosphorylation to acyclovir triphosphate, leading to chain termination and inhibition of herpes simplex virus replication.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
Acyclovir 200 mg orally 5 times daily for 10 days for initial genital herpes; 400 mg orally twice daily for suppressive therapy; 5-10 mg/kg IV every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
2.5–3.3 hours in adults with normal renal function; prolonged to 10–20 hours in anuria (CrCl <10 mL/min); requires dose adjustment in renal impairment
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Renal: ~90% as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<2%)
Category C
Category C
Antiviral
Antiviral